European Respiratory Society guidelines for the management of adult bronchiectasis.
Eva Polverino, Pieter C Goeminne, Melissa J McDonnell...
https://pubmed.ncbi.nlm.nih.gov/28889110/Actively Recruiting
Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2025-04-01
364
Participants Needed
58
Research Sites
N/A
Total Duration
This research aims to study the long-term effects of successfully removing Pseudomonas aeruginosa PA infections in adults with bronchiectasis. It builds on a previous trial called ERASE that tested inhaled Tobramycin to clear PA in patients newly diagnosed with this infection. The goal is to see if eradicating PA improves health outcomes over a longer period. The study involves an extended observation period totaling 36 months, combining the first 9 months from the initial ERASE trial with an additional 27 months of follow-up. Participants are grouped based on whether they successfully cleared PA in the prior study. There is no new treatment given during this follow-up phase it is an observational study tracking patients over time. Participants will be monitored regularly for quality of life, lung function, frequency and severity of lung flare-ups, hospital visits, and treatment costs. Researchers will also check sputum samples at various time points up to 36 months to detect any return of PA infection. This comprehensive follow-up will help understand the long-term benefits and challenges after PA eradication in bronchiectasis patients.
CONDITIONS
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
J
Jin-Fu Xu
J
Jin-Fu Xu, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shanghai Pulmonary Hospital, Shanghai, China
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 36 months
Participants are observed over a long period to assess the long-term impact of Tobramycin inhalation solution on their bronchiectasis, including lung function, quality of life, frequency of pulmonary exacerbations, hospitalization rates, and treatment costs.
Regular visits at 6, 9, 12, 15, 21, 27, and 36 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Eva Polverino, Pieter C Goeminne, Melissa J McDonnell...
https://pubmed.ncbi.nlm.nih.gov/28889110/Yong-Hua Gao, Hai-Wen Lu, Hui-Zhen Zheng...
https://pubmed.ncbi.nlm.nih.gov/38410702/Mariana Conceição, Michal Shteinberg, Pieter Goeminne...
https://pubmed.ncbi.nlm.nih.gov/38296344/Adam T Hill, Anita L Sullivan, James D Chalmers...
https://pubmed.ncbi.nlm.nih.gov/30545985/Shanghai Pulmonary Hospital, Shanghai, China
Lead Sponsor